Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sinarest CCF New
- Development stage
- Unknown
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sinarest CCF New is an approved oral fixed-dose combination small-molecule drug manufactured and marketed by Centaur Pharmaceuticals. It is formulated as a capsule (including softgel) and is indicated for the temporary relief of symptoms associated with the common cold, hay fever (allergic rhinitis), and upper respiratory allergies, including dry cough, nasal congestion, runny nose, sneezing, and throat irritation. The combination consists of three active ingredients: chlorpheniramine maleate (an antihistamine), dextromethorphan hydrobromide (a cough suppressant), and phenylephrine hydrochloride (a nasal decongestant). Chlorpheniramine maleate acts as an antagonist at histamine H1 receptors to alleviate allergic symptoms like sneezing and runny nose. Dextromethorphan hydrobromide acts as a sigma-1 receptor agonist and an NMDA receptor antagonist to suppress the cough reflex in the brainstem. Phenylephrine hydrochloride acts as an agonist at alpha-1 adrenergic receptors to constrict blood vessels in the nasal mucosa, thereby reducing nasal congestion.
- Brand names
- SinarestSinarest CCFSinarest CCF New
- Other names
- Sinarest CCF New CapsuleSinarest CCF New Softgel Capsulechlorpheniramine + dextromethorphan + phenylephrinechlorpheniramine maleate + dextromethorphan hydrobromide + phenylephrine hydrochloride
02
Targets
ADRA1A (α1A)HRH1 (Histamine H1 Receptor)NMDAR (Glutamate receptor ionotropic, NMDA)SIGMAR1 (Sigma non-opioid intracellular receptor 1)
Beyond the preview
Go deeper on Sinarest CCF New.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinarest CCF New.